— CEO to Participate on “Trust Your Gut” – Therapeutic Opportunities from the Microbiome Panel —
— Company Voted “Most Distinguished Public Company” as part of the Buzz of BIO Contest —
ROCKVILLE, Md., Feb. 3, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 9, 2015, at 1:30 p.m. (ET) at the Waldorf Astoria (Conrad room) in New York.
A live webcast of Synthetic Biologics’ presentation may be accessed by logging onto the internet at http://www.veracast.com/webcasts/bio/ceoinvestor2015/42118168151.cfm. After the presentation, a replay will be archived and accessible for 90 days at the same website.
Jeffrey Riley will also participate on the “Trust Your Gut”—Therapeutic Opportunities from the Microbiome panel at the 2015 BIO CEO & Investor Conference on Tuesday, February 10, 2015, at 8:00 a.m. (ET) in the Waldorf Astoria Jade room. This moderated panel will review emerging data that the bacterial colonies of the digestive system (the gut microbiome) influence far more non-digestive systems than previously believed, while creating natural antibiotics and other compounds that may be an underleveraged source for efficient drug discovery.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage biotechnology company developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. The Company is developing an oral biologic to protect the gastrointestinal (GI) microflora from the effects of intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral statin treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS) and a monoclonal antibody combination for the treatment of Pertussis being developed in collaboration with Intrexon Corporation (NYSE: XON). In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics’ website at www.therivabio.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-present-at-the-2015-bio-ceo–investor-conference-300029609.html
SOURCE Synthetic Biologics, Inc.
Released February 3, 2015